Skip to main content

Table 3 COX-2 genotypes, NSAIDs use, and risk for breast cancer: Long Island Breast Cancer Study Project, 1996 to 1997

From: Genetic polymorphisms in the cyclooxygenase-2 gene, use of nonsteroidal anti-inflammatory drugs, and breast cancer risk

 

No use

Ever use

 

Cases/controls

OR (95% CI)a

Cases/controls

OR (95% CI)a

Aspirin

COX-2 .926 (rs20417)

GG

511/484

1.0 (ref.)

138/156

0.8 (0.6–1.0)

GC + CC

285/291

0.9 (0.8–1.1)

84/93

0.8 (0.6–1.1)

COX-2 .5209 (rs20432)

TT

521/485

1.0 (ref.)

145/160

0.8 (0.6–1.0)

TG + GG

275/282

0.9 (0.7–1.1)

78/86

0.8 (0.6–1.1)

COX-2 .8473 (rs5275)

TT

363/332

1.0 (ref.)

98/101

0.8 (0.6–1.1)

TC + CC

436/439

0.9 (0.8–1.1)

124/148

0.7 (0.5–0.9)b

Any NSAID

COX-2 .926 (rs20417)

GG

418/412

1.0 (ref.)

235/240

0.9 (0.7–1.1)

GC + CC

245/249

0.9 (0.8–1.2)

126/137

0.8 (0.6–1.1)

COX-2 .5209 (rs20432)

TT

427/417

1.0 (ref.)

243/240

0.9 (0.7–1.1)

TG + GG

237/237

1.0 (0.8–1.2)

118/133

0.8 (0.6–1.1)

COX-2 .8473 (rs5275)

TT

290/285

1.0 (ref.)

175/155

1.1 (0.8–1.4)

TC + CC

376/371

1.0 (0.8–1.3)

186/223

0.8 (0.6–1.0)

  1. aAdjusted for age at reference. bMultiplicative interaction term was not significant (P for interaction = 0.69), by Wald statistic. CI, confidence interval; OR, odds ratio.
Back to article page

Breast Cancer Research

ISSN: 1465-542X

Contact us